Maine Nurse Practitioner Loses DEA Registration Rights
Published Date: 6/10/2026
Notice
Summary
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA registration revoked for Vermillion
Ashley Vermillion, N.P., had her DEA Certificate of Registration No. MV750134 revoked, so she cannot prescribe, dispense, or otherwise handle controlled substances under her DEA registration. The agency found her Maine nursing license expired on July 8, 2025, and the revocation is effective July 10, 2026.
Pending and future Maine applications denied
The Order also denies any pending applications of Ashley Vermillion, N.P., to renew or modify her DEA registration and denies any other pending application for additional registration in Maine. That denial is issued along with the revocation and is effective July 10, 2026.
Right to seek reconsideration within 15 days
Ashley Vermillion may file a properly supported motion for reconsideration of the factual finding that her Maine nursing license is expired. Any such motion and response must be filed and served by email within fifteen calendar days of the date of this Order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
Previous / Next Documents
Previous: 2026-11571 — Notice of Availability of Designation of Chinese Military Companies
The U.S. Department of Defense just named several Chinese companies as military-linked and operating in the U.S. This means these companies, like Qihoo 360 and CH UAV, are officially flagged for their ties to China’s military. The list updates every year through 2030, so businesses and investors should watch out for potential restrictions or impacts on deals involving these companies.
Next: 2026-11573 — Certain Smart Devices; Notice of Institution of Investigation
Cerence Operating Company has asked the U.S. International Trade Commission to investigate certain smart devices that might be using their patented technology without permission. This could lead to restrictions on importing and selling these devices in the U.S., possibly affecting companies and shoppers soon. The investigation started on June 5, 2026, and could bring big changes to the smart device market and money flow.